Neil Gregory Almstead Ptc Therapeutics, Inc. (PTCT) insider trading activity

Neil Gregory Almstead is CHIEF TECHNICAL OPS OFFICER of PTC THERAPEUTICS, INC.. Currently has a direct ownership of 86,202 shares of PTCT, which is worth approximately $3.9 Million. The most recent transaction as insider was on Dec 02, 2024, when has been sold 69,550 shares (Common Stock) at a price of $52.32 per share, resulting in proceeds of $3,638,856. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86.2K

0% 3M change

34.8% 12M change

Total Value Held $3.9 Million

Neil Gregory Almstead Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 02 2024	SELL Open market or private sale	$3,638,856 $52.32 p/Share	69,550 Reduced 44.65%	86,202 Common Stock
Dec 02 2024	BUY Exercise of conversion of derivative security	$3,547,050 $51.0 p/Share	69,550 Added 31.23%	153,158 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	25,000 Added 22.48%	86,202 Common Stock
Jan 30 2024	SELL Open market or private sale	$16,840 $27.25 p/Share	618 Reduced 1.0%	61,202 Common Stock
Jan 09 2024	SELL Open market or private sale	$44,124 $29.01 p/Share	1,521 Reduced 2.4%	61,820 Common Stock
Jan 08 2024	SELL Open market or private sale	$35,399 $28.64 p/Share	1,236 Reduced 1.91%	63,341 Common Stock
Jan 31 2023	SELL Open market or private sale	$28,746 $45.63 p/Share	630 Reduced 0.98%	63,949 Common Stock
Jan 11 2023	SELL Open market or private sale	$16,989 $44.36 p/Share	383 Reduced 0.59%	64,579 Common Stock
Jan 10 2023	SELL Open market or private sale	$20,305 $42.93 p/Share	473 Reduced 0.72%	64,962 Common Stock
Jan 09 2023	SELL Open market or private sale	$29,828 $41.66 p/Share	716 Reduced 1.08%	65,435 Common Stock
Jan 05 2023	BUY Grant, award, or other acquisition	-	17,000 Added 20.44%	66,151 Common Stock
Feb 01 2022	SELL Open market or private sale	$24,200 $40.0 p/Share	605 Reduced 1.22%	48,853 Common Stock
Jan 07 2022	SELL Open market or private sale	$29,121 $38.52 p/Share	756 Reduced 2.11%	35,058 Common Stock
Jan 07 2022	BUY Grant, award, or other acquisition	-	14,400 Added 22.55%	49,458 Common Stock
Feb 01 2021	SELL Open market or private sale	$55,422 $56.96 p/Share	973 Reduced 2.64%	35,814 Common Stock
Jan 06 2021	BUY Grant, award, or other acquisition	-	10,200 Added 21.71%	36,787 Common Stock
Jan 05 2021	SELL Open market or private sale	$31,310 $62.37 p/Share	502 Reduced 1.85%	26,587 Common Stock
Jan 04 2021	SELL Open market or private sale	$6,290,065 $60.81 p/Share	103,438 Reduced 79.25%	27,089 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$1,833,956 $17.73 p/Share	103,438 Added 57.9%	75,214 Common Stock
Nov 04 2020	SELL Open market or private sale	$1,443,720 $60.0 p/Share	24,062 Reduced 47.04%	27,089 Common Stock
Nov 04 2020	BUY Exercise of conversion of derivative security	$270,216 $11.23 p/Share	24,062 Added 32.95%	48,964 Common Stock

NGA

Neil Gregory Almstead

CHIEF TECHNICAL OPS OFFICER

South Plainfield, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTCT shares.

Notify only if

Value

Insider Trading

Get notified when an Ptc Therapeutics, Inc. insider buys or sells PTCT shares.

Notify only if

Operation

Value

Type

News

Receive news related to PTC THERAPEUTICS, INC.

Track Activities on PTCT

Account